Plasma adrenomedullin as an independent predictor of future cardiovascular events in high-risk patients: Comparison with C-reactive protein and adiponectin

Peptides

Volumn 29, Issue 4, 2008, Pages 599-605

  Nishida, Hidenori ^a   Horio, Takeshi ^a   Suzuki, Yoshihiko ^b   Iwashima, Yoshio ^c   Kamide, Kei ^a   Kangawa, Kenji ^a   Kawano, Yuhei ^a  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^b UNIVERSITY OF MIYAZAKI   (Japan)

^c OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Adiponectin; Adrenomedullin; C reactive protein; Cardiovascular disease; Morbidity

Indexed keywords

ADIPONECTIN; ADRENOMEDULLIN; C REACTIVE PROTEIN; CREATININE;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CREATININE CLEARANCE; FEMALE; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROTEIN BLOOD LEVEL; STROKE; TRANSIENT ISCHEMIC ATTACK;

ADIPONECTIN; ADRENOMEDULLIN; AGED; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; RISK FACTORS;

EID: 40249088167     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2007.12.006     Document Type: Article

References (47)

1. Best L.G., Zhang Y., Lee E.T., Yeh J.L., Cowan L., Palmieri V., et al. C-reactive protein as a predictor of cardiovascular risk in a population with a high prevalence of diabetes: the Strong Heart Study. Circulation 112 (2005) 1289-1295
2. Cavusoglu E., Ruwende C., Chopra V., Yanamadala S., Eng C., Clark L.T., et al. Adiponectin is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction in patients presenting with chest pain. Eur Heart J 27 (2006) 2300-2309
3. Cockcroft D.W., and Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 16 (1976) 31-41
4. Efstathiou S.P., Tsioulos D.I., Tsiakou A.G., Gratsias Y.E., Pefanis A.V., and Mountokalakis T.D. Plasma adiponectin levels and five-year survival after first-ever ischemic stroke. Stroke 36 (2005) 1915-1919
5. Frystyk J., Berne C., Berglund L., Jensevik K., Flyvbjerg A., and Zethelius B. Serum adiponectin is a predictor of coronary heart disease: a population-based 10-year follow-up study in elderly men. J Clin Endocrinol Metab 92 (2007) 571-576
6. Horio T., Nishikimi T., Yoshihara F., Nagaya N., Matsuo H., Takishita S., et al. Production and secretion of adrenomedullin in cultured rat cardiac myocytes and nonmyocytes: stimulation by interleukin-1β and tumor necrosis factor-α. Endocrinology 139 (1998) 4576-4580
7. Hosomi N., Ohyama H., Takahashi T., Shinomiya K., Naya T., Ban C.R., et al. Plasma adrenomedullin and carotid atherosclerosis in atherothrombotic ischemic stroke. J Hypertens 22 (2004) 1945-1951
8. Ishimitsu T., Nishikimi T., Saito Y., Kitamura K., Eto T., Kangawa K., et al. Plasma levels of adrenomedullin, a newly identified hypotensive peptide, in patients with hypertension and renal failure. J Clin Invest 94 (1994) 2158-2161
9. Iwashima Y., Horio T., Kumada M., Suzuki Y., Kihara S., Rakugi H., et al. Adiponectin and renal function, and implication as a risk of cardiovascular disease. Am J Cardiol 98 (2006) 1603-1608
10. Iwashima Y., Horio T., Suzuki Y., Kihara S., Rakugi H., Kangawa K., et al. Adiponectin and inflammatory markers in peripheral arterial occlusive disease. Atherosclerosis 188 (2006) 384-390
11. Jougasaki M., Wei C.M., McKinley L.J., and Burnett Jr. J.C. Elevation of circulating and ventricular adrenomedullin in human congestive heart failure. Circulation 92 (1995) 286-289
12. Katayama T., Nakashima H., Furudono S., Honda Y., Suzuki S., and Yano K. Evaluation of neurohumoral activation (adrenomedullin, BNP, catecholamines, etc.) in patients with acute myocardial infarction. Intern Med 43 (2004) 1015-1022
13. Kistorp C., Faber J., Galatius S., Gustafsson F., Frystyk J., Flyvbjerg A., et al. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 112 (2005) 1756-1762
14. Kitamura K., Kangawa K., Kawamoto M., Ichiki Y., Nakamura S., Matsuo H., et al. Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun 192 (1993) 553-560
15. Kobayashi K., Kitamura K., Hirayama N., Date H., Kashiwagi T., Ikushima I., et al. Increased plasma adrenomedullin in acute myocardial infarction. Am Heart J 131 (1996) 676-680
16. Koenig W., Khuseyinova N., Baumert J., Meisinger C., and Lowel H. Serum concentrations of adiponectin and risk of type 2 diabetes mellitus and coronary heart disease in apparently healthy middle-aged men: results from the 18-year follow-up of a large cohort from southern Germany. J Am Coll Cardiol 48 (2006) 1369-1377
17. Kohno M., Hanehira T., Kano H., Horio T., Yokokawa K., Ikeda M., et al. Plasma adrenomedullin concentrations in essential hypertension. Hypertension 27 (1996) 102-107
18. Lawlor D.A., Davey Smith G., Ebrahim S., Thompson C., and Sattar N. Plasma adiponectin levels are associated with insulin resistance, but do not predict future risk of coronary heart disease in women. J Clin Endocrinol Metab 90 (2005) 5677-5683
19. Libby P., Ridker P.M., and Maseri A. Inflammation and atherosclerosis. Circulation 105 (2002) 1135-1143
20. McFarlane S.I., Banerji M., and Sowers J.R. Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab 86 (2001) 713-718
21. Menon V., Li L., Wang X., Greene T., Balakrishnan V., Madero M., et al. Adiponectin and mortality in patients with chronic kidney disease. J Am Soc Nephrol 17 (2006) 2599-2606
22. Miyao Y., Nishikimi T., Goto Y., Miyazaki S., Daikoku S., Morii I., et al. Increased plasma adrenomedullin levels in patients with acute myocardial infarction in proportion to the clinical severity. Heart 79 (1998) 39-44
23. Nagaya N., Nishikimi T., Uematsu M., Yoshitomi Y., Miyao Y., Miyazaki S., et al. Plasma adrenomedullin as an indicator of prognosis after acute myocardial infarction. Heart 81 (1999) 483-487
24. Nishikimi T., Horio T., Kohmoto Y., Yoshihara F., Nagaya N., Inenaga T., et al. Molecular forms of plasma and urinary adrenomedullin in normal, essential hypertension and chronic renal failure. J Hypertens 19 (2001) 765-773
25. Nishikimi T., Saito Y., Kitamura K., Ishimitsu T., Eto T., Kangawa K., et al. Increased plasma levels of adrenomedullin in patients with heart failure. J Am Coll Cardiol 26 (1995) 1424-1431
26. Ogita T., Hashimoto E., Yamasaki M., Nakaoka T., Matsuoka R., Kira Y., et al. Hypoxic induction of adrenomedullin in cultured human umbilical vein endothelial cells. J Hypertens 19 (2001) 603-608
27. Ohta H., Tsuji T., Asai S., Tanizaki S., Sasakura K., Teraoka H., et al. A simple immunoradiometric assay for measuring the entire molecules of adrenomedullin in human plasma. Clin Chim Acta 287 (1999) 131-143
28. Pirro M., Bergeron J., Dagenais G.R., Bernard P.M., Cantin B., Despres J.P., et al. Age and duration of follow-up as modulators of the risk for ischemic heart disease associated with high plasma C-reactive protein levels in men. Arch Intern Med 161 (2001) 2474-2480
29. Pousset F., Masson F., Chavirovskaia O., Isnard R., Carayon A., Golmard J.L., et al. Plasma adrenomedullin, a new independent predictor of prognosis in patients with chronic heart failure. Eur Heart J 21 (2000) 1009-1014
30. Richards A.M., Doughty R., Nicholls M.G., MacMahon S., Sharpe N., Murphy J., et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. J Am Coll Cardiol 37 (2001) 1781-1787
31. Ridker P.M., Cushman M., Stampfer M.J., Tracy R.P., and Hennekens C.H. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336 (1997) 973-979
32. Ridker P.M., Hennekens C.H., Buring J.E., and Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342 (2000) 836-843
33. Ridker P.M., Rifai N., Rose L., Buring J.E., and Cook N.R. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347 (2002) 1557-1565
34. Rutter M.K., Meigs J.B., Sullivan L.M., D'Agostino Sr. R.B., and Wilson P.W.F. C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation 110 (2004) 380-385
35. Sattar N., Wannamethee G., Sarwar N., Tchernova J., Cherry L., Wallace A.M., et al. Adiponectin and coronary heart disease: a prospective study and meta-analysis. Circulation 114 (2006) 623-629
36. Schulze M.B., Rimm E.B., Li T., Rifai N., Stampfer M.J., and Hu F.B. C-reactive protein and incident cardiovascular events among men with diabetes. Diabetes Care 27 (2004) 889-894
37. Schulze M.B., Shai I., Rimm E.B., Li T., Rifai N., and Hu F.B. Adiponectin and future coronary heart disease events among men with type 2 diabetes. Diabetes 54 (2005) 534-539
38. Sugo S., Minamino N., Kangawa K., Miyamoto K., Kitamura K., Sakata J., et al. Endothelial cells actively synthesize and secrete adrenomedullin. Biochem Biophys Res Commun 201 (1994) 1160-1166
39. Sugo S., Minamino N., Shoji H., Kangawa K., Kitamura K., Eto T., et al. Production and secretion of adrenomedullin from vascular smooth muscle cells: augmented production by tumor necrosis factor-α. Biochem Biophys Res Commun 203 (1994) 719-726
40. Suzuki Y., Horio T., Hayashi T., Nonogi H., Kitamura K., Eto T., et al. Plasma adrenomedullin concentration is increased in patients with peripheral arterial occlusive disease associated with vascular inflammation. Regul Pept 118 (2004) 99-104
41. Suzuki Y., Horio T., Nonogi H., Hayashi T., Kitamura K., Eto T., et al. Adrenomedullin as a sensitive marker for coronary and peripheral arterial complications in patients with atherosclerotic risks. Peptides 25 (2004) 1321-1326
42. van der Meer I.M., de Maat M.P., Kiliaan A.J., van der Kuip D.A., Hofman A., and Witteman J.C. The value of C-reactive protein in cardiovascular risk prediction: the Rotterdam Study. Arch Intern Med 163 (2003) 1323-1328
43. Wang X., Yue T.L., Barone F.C., White R.F., Clark R.K., Willette R.N., et al. Discovery of adrenomedullin in rat ischemic cortex and evidence for its role in exacerbating focal brain ischemic damage. Proc Natl Acad Sci USA 92 (1995) 11480-11484
44. Wilson P.W., Nam B.H., Pencina M., D'Agostino Sr. R.B., Benjamin E.J., and O'Donnell C.J. C-reactive protein and risk of cardiovascular disease in men and women from the Framingham Heart Study. Arch Intern Med 165 (2005) 2473-2478
45. Yoshihara F., Horio T., Nakamura S., Yoshii M., Ogata C., Nakahama H., et al. Adrenomedullin reflects cardiac dysfunction, excessive blood volume, and inflammation in hemodialysis patients. Kidney Int 68 (2005) 1355-1363
46. Yoshihara F., Horio T., Nishikimi T., Matsuo H., and Kangawa K. Possible involvement of oxidative stress in hypoxia-induced adrenomedullin secretion in cultured rat cardiomyocytes. Eur J Pharmacol 436 (2002) 1-6
47. Zoccali C., Mallamaci F., Tripepi G., Benedetto F.A., Cutrupi S., Parlongo S., et al. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 13 (2002) 134-141